Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis - PubMed (original) (raw)
Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis
A L Williams et al. Gastroenterology. 1988 Sep.
Abstract
The ratio of the serum aspartate to alanine amino-transferase levels (AST/ALT) is often used as a clue to the etiology of the underlying liver disease. This ratio is usually greater than 2.0 in alcoholic liver disease and less than 1.0 in patients with chronic hepatitis and chronic cholestatic syndromes. We analyzed the AST/ALT ratio in 177 patients with various forms of nonalcoholic chronic liver disease who underwent medical evaluation and percutaneous liver biopsy. In the majority of cases of chronic viral hepatitis, the AST/ALT ratio was less than 1.0. However, there was a statistically significant correlation between the AST/ALT ratio and the presence of cirrhosis. Among 100 patients with chronic type B hepatitis, the mean AST/ALT ratio was 0.59 in those without cirrhosis and 1.02 in those with cirrhosis. Furthermore, the AST/ALT ratio often rose to greater than 1.0 when cirrhosis first became manifest. Thus, the finding of an AST/ALT ratio of greater than 1.0 in a patient with nonalcoholic liver disease should suggest the presence of cirrhosis. In addition, the use of the AST/ALT ratio as a means of separating alcoholic and nonalcoholic liver disease must be tempered with the knowledge that this ratio may be less helpful in the presence of cirrhosis.
Similar articles
- Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?
Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Park GJ, et al. J Gastroenterol Hepatol. 2000 Apr;15(4):386-90. doi: 10.1046/j.1440-1746.2000.02172.x. J Gastroenterol Hepatol. 2000. PMID: 10824882 - AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C.
Reedy DW, Loo AT, Levine RA. Reedy DW, et al. Dig Dis Sci. 1998 Sep;43(9):2156-9. doi: 10.1023/a:1018888021118. Dig Dis Sci. 1998. PMID: 9753286 - Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.
Deghady A, Abdou A, El-Neanaey WA, Diab I. Deghady A, et al. Genet Test Mol Biomarkers. 2012 Jun;16(6):531-5. doi: 10.1089/gtmb.2011.0098. Epub 2012 Feb 21. Genet Test Mol Biomarkers. 2012. PMID: 22352690 - [Management of asymptomatic elevated serum aminotransferase levels, particularly in nonalcoholic steatohepatitis].
Oldenburg B, Van Berge Henegouwen GP. Oldenburg B, et al. Ned Tijdschr Geneeskd. 1999 Mar 6;143(10):506-9. Ned Tijdschr Geneeskd. 1999. PMID: 10321258 Review. Dutch. - AST to ALT ratio and arterial stiffness in non-fatty liver Japanese population:a secondary analysis based on a cross-sectional study.
Liu Y, Zhao P, Cheng M, Yu L, Cheng Z, Fan L, Chen C. Liu Y, et al. Lipids Health Dis. 2018 Dec 3;17(1):275. doi: 10.1186/s12944-018-0920-4. Lipids Health Dis. 2018. PMID: 30509277 Free PMC article. Review.
Cited by
- HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB-4 scores.
Huynh T, Ma S, Hu KQ. Huynh T, et al. Hepatol Commun. 2022 Dec;6(12):3496-3504. doi: 10.1002/hep4.2098. Epub 2022 Oct 11. Hepatol Commun. 2022. PMID: 36221305 Free PMC article. - Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients-A Cohort from the North-Eastern Part of Romania.
Grecu LI, Sultana C, Pavel-Tanasa M, Ruta SM, Chivu-Economescu M, Matei L, Ursu RG, Iftimi E, Iancu LS. Grecu LI, et al. Microorganisms. 2023 Nov 30;11(12):2895. doi: 10.3390/microorganisms11122895. Microorganisms. 2023. PMID: 38138039 Free PMC article. - Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients.
Li X, Xu H, Gao P. Li X, et al. Med Sci Monit. 2019 Sep 27;25:7243-7250. doi: 10.12659/MSM.918784. Med Sci Monit. 2019. PMID: 31558693 Free PMC article. - Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care.
Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Dobbie LJ, et al. J Clin Med. 2021 Dec 9;10(24):5755. doi: 10.3390/jcm10245755. J Clin Med. 2021. PMID: 34945051 Free PMC article. - NAFLD mark: an accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients.
Mohamed AA, El-Demery A, Al-Hussain E, Mousa S, Halim AA, Mostafa SM, Abdelghany RS, Mahmoud SM, Elkady MA, Raafat K, Hassnine AA, Omran MM. Mohamed AA, et al. J Genet Eng Biotechnol. 2021 Oct 18;19(1):157. doi: 10.1186/s43141-021-00257-5. J Genet Eng Biotechnol. 2021. PMID: 34661762 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical